[1] CHEN Y, LUO D, GAO R, et al.The Sentinels of Coronary Artery Disease: Heterogeneous Monocytes[J]. Frontiers in Immunology, 2025, 16: 1428978. [2] KATTA N, LOETHEN T, LAVIE CJ, et al.Obesity and Coronary Heart Disease: Epidemiology, Pathology, and Coronary Artery Imaging[J]. Current Problems in Cardiology, 2021, 46(3): 100655. [3] National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Chinese Cardiovascular Health and Disease Report 2023 Summary[J]. Chinese Circulation Journal(中国循环杂志), 2024, 39(7): 625-660. [4] HUO Y, WU ZG, LIN Q.Expert Consensus on Clinical Application of Tongxinluo in Prevention and Treatment of Coronary Heart Disease[J]. Chinese Journal of Interventional Cardiology(中国介入心脏病学杂志), 2024, 32(4): 181-190. [5] TIAN LX, DOU BM, LI LC, et al.Analysis of GUO Yi's Experience in Treating Coronary Heart Disease[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2024, 39(1): 225-228. [6] LIU D, LIU Y.Professor GUO Weiqin’s Treatment of Coronary Heart Disease with Anxiety and Depression Based on“Nourishing Heart and Regulating Liver”Method[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease(中西医结合心脑血管病杂志), 2025, 23(4): 633-636. [7] YU TT, QIAN TM, ZOU GL, et al.Clinical Experience of National TCM Master LU Fang in Treating Coronary Heart Disease[J]. Journal of Emergency in Traditional Chinese Medicine(中国中医急症), 2024, 33(9): 1654-1656, 1660. [8] DU RL, HE QY, SU QM, et al.Research Status and Hotspot Analysis of Classical Prescriptions in Treating Coronary Heart Disease[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease(中西医结合心脑血管病杂志), 2025, 23(3): 328-336. [9] WANG XJ, ZHANG WT, GUO MD, et al.Experience of Professor WENG Wei-Liang in Treatment of Senile Coronary Heart Disease[J]. Chinese Archives of Traditional Chinese Medicine(中华中医药学刊), 2023, 41(5): 124-127. [10] HOU SZ, XU WJ, LAN TH, et al.Mechanism of Quyu Huatan Formula in Treating Coronary Heart Disease Based on Network Pharmacology and Molecular Docking[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease(中西医结合心脑血管病杂志), 2023, 21(9): 1543-1552. [11] LIAN K, LIAO XQ, MENG LC, et al.Visualized Analysis of Clinical Research on TCM Intervention in Coronary Heart Disease[J]. China Medical Herald(中国医药导报), 2025, 22(2): 124-131. [12] CAO XH, CHEN YJ, CHEN C.Medication Rules of TCM in Treating Coronary Atherosclerotic Heart Disease with Bradyarrhythmia Based on Data Mining[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2024, 16(24): 25-30. [13] HUO YH, ZHANG J, ZHOU LR, et al.Medication Rules and Mechanism of TCM in Treating Coronary Heart Disease with Hyperlipidemia Based on R Language and Network Pharmacology[J]. West China Journal of Pharmaceutical Sciences(华西药学杂志), 2024, 39(6): 655-663. [14] YANG RL, WANG FR.New Progress in Pharmacological and Mechanism Research of Danshen and Its Preparations in Treating Coronary Heart Disease[J]. Chinese Archives of Traditional Chinese Medicine(中华中医药学刊), 2024, 42(11): 164-169. [15] WANG J, LI L, LIU B, et al.Mechanism of Danshen Decoction in Treating Heart Failure Based on Network Pharmacology and Experimental Verification[J]. Chinese Pharmacological Bulletin(中国药理学通报), 2024, 40(9): 1773-1780. [16] HU MZ, LI XL, JIN JY, et al.Effects of Danshen Decoction Pretreatment on Cardiac Hemodynamics and Mitochondrial Energy Metabolism in Rats with Myocardial Ischemia Reperfusion Injury[J]. Chinese Traditional Patent Medicine(中成药), 2022, 44(7): 2119-2125. [17] LIU MN, MAO LS, LI ZY, et al.Mechanism of Danshen Decoction in Improving Hypoxia/Reoxygenation-Induced Cardiomyocyte Injury by Regulating Mitochondrial mPTP Opening[J]. Journal of Chinese Medicinal Materials(中药材), 2024, (12): 3108-3113. [18] ZHANG YK, FENG YN, BIAN JQ, et al.Mechanism of Danshen Decoction on Platelet Activation in Hyperlipidemia Model Rats Based on Proteomics[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2024, 30(8): 1-8. [19] HE LJ, CHE QF.Clinical Observation of Aspirin, Benazepril, Metoprolol Combined with Modified Danshen Decoction in the Treatment of Angina Pectoris of Coronary Heart Disease[J]. Guangming Journal of Chinese Medicine(光明中医), 2020, 35(13): 2062-2064. [20] YAO CW, SHI M, SUI Y, et al.To Observe the Curative Effect of Treating Patients with Inferior Wall Ischemic Coronary Heart Disease from the Perspective of Treating Heart and Stomach Together[J]. Journal of Emergency in Traditional Chinese Medicine(中国中医急症), 2018, 27(12): 2171-2173. [21] GUO SY.Clinical Study on Treatment of Stable Angina Pectoris with Danshen Decoction Adjusted Formulation[D]. Harbin: Heilongjiang University of Traditional Chinese Medicine, 2018. [22] HUANG YC.Effect of Danshen Decoction Combined with Metoprolol on Coronary Heart Disease and Its Influence on Inflammation and Blood Lipid Indexes[J]. Heilongjiang Medicine and Pharmacy(黑龙江医药科学), 2019, 42(2): 180-181. [23] QIU WF, LIU J, XIANG ZX, et al.Effect of Modified Danshen Decoction on Vascular Endothelial Cell Morphology after Coronary Heart Disease Injury[J]. Shaanxi Journal of Traditional Chinese Medicine(陕西中医), 2016, 37(8): 1042-1043. [24] ZHANG XJ.Effect of Modified Danshen Decoction Combined with Conventional Western Medicine on Angina Pectoris of Coronary Heart Disease[J]. Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine(中西医结合心血管病电子杂志), 2015, 3(27): 57-58. [25] HE YD.Effect and Adverse Reaction of Modified Danshen Decoction Combined with Western Medicine on Patients with Coronary Heart Disease Angina Pectoris and Heart Blood Stasis Syndrome[J]. Henan Medical Research(河南医学研究), 2017, 26(8): 1466-1467. [26] HUANG CZ, LIANG YP.Effective Observation on Treating Angina Pectoris of the Xinxue Yuzu Type with Danshen Decoction Plus Western Medicine[J]. Clinical Journal of Chinese Medicine(中医临床研究), 2019, 11(4): 100-102. [27] TANG MS, HUANG ZD, XIANG ZJ, et al.Effect of Modified Danshen Decoction Combined with Western Medicine on 68 Cases of Coronary Heart Disease Angina Pectoris and Heart Blood Stasis[J]. Journal of Traditional Chinese Medicine(中医杂志), 2015, 56(5): 395-397. [28] FAN KB.Clinical Observation of Modified Danshen Decoction Combined with Western Medicine in the Treatment of Coronary Heart Disease Angina Pectoris and Heart Blood Stasis Syndrome[J]. Health Horizon(健康大视野), 2018(13): 43. [29] WAN L, SHI C, SUN YB, et al.Clinical Efficacy of Modified Danshen Decoction Combined with Western Medicine in the Treatment of Stable Angina Pectoris of Qi Stagnation and Blood Stasis Type[J]. Journal of Practical Traditional Chinese Internal Medicine(实用中医内科杂志), 2020, 34(11): 78-81. [30] LI GH.Effect of Modified Danshen Decoction on Unstable Angina Pectoris[J]. Inner Mongolia Journal of Traditional Chinese Medicine(内蒙古中医药), 2014, 33(20): 23-24. [31] DING D, DONG XJ, LIU PZ, et al.41 Cases of Angina Pectoris of Coronary Heart Disease Treated with Modified Danshen Decoction[J]. Journal of Changchun University of Chinese Medicine(长春中医药大学学报), 2007(3): 38. [32] DONG Z, ZHANG YJ, CHEN HJ, et al.Clinical Randomized Controlled Trial of Modified Danshen Decoction for the Treatment of Angina Pectoris of Coronary Heart Disease Complicated with Depression and Anxiety and Differentiated as Syndrome of Qi Stagnation and Blood Stasis[J]. Journal of Guangzhou University of Traditional Chinese Medicine(广州中医药大学学报), 2021, 38(7): 1329-1334. [33] XU MC, ZHANG JQ, LONG HL, et al.Clinical Observation of 40 Cases of Unstable Angina Pectoris of Coronary Heart Disease Treated with Integrated Traditional Chinese and Western Medicine[J]. Guiding Journal of Traditional Chinese Medicine and Pharmacy(中医药导报), 2011, 17(5): 111-113. [34] HE ZC, HUANG ZD.A Summary of 37 Cases of Stable Angina Pectoris Treated with Integrated Traditional Chinese and Western Medicine[J]. Hunan Journal of Traditional Chinese Medicine(湖南中医杂志), 2010, 26(5): 15-16. [35] PAGE M J, MOHER D, BOSSUYT P M, et al. PRISMA2020 Explan- ation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews[J]. British Medical Journal, 2021, 372: n160. [36] PAGE MJ, MCKENZIE JE, BOSSUYT PM, et al.The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews[J]. British Medical Journal, 2021, 372: n71. [37] Ministry of Health of the People’s Republic of China, Diagnostic Criteria for Coronary Atherosclerotic Heart Disease[S] Diagnostic Criteria for Coronary Atherosclerotic Heart Disease[S]. Beijing: Standards Press of China. [38] HIGGINS JP, ALTAM DG, GØTZSCHE PC, et al. The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomized Trials[J]. British Medical Journal, 2011, 343: d5928. [39] BALSHEM H, HELFANDA M, J.SCHUNEMANN H, et al. GRADE Guidelines: 3. Rating the Quality of Evidence[J]. Chinese Journal of Evidence-based Medicine(中国循证医学杂志), 2011,11(4): 451-455. [40] LIAO CH, XUE XH.Meta-Analysis of Clinical Efficacy and Safety of Supplemented Danshen Decoction Combined with Conventional Western Medicine in Treating Angina Pectoris of Coronary Heart Disease[J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease(中西医结合心脑血管病杂志), 2019, 17(11): 1619-1622. |